“With two clinical-stage programs advancing, Maze continues to execute with focus and discipline,” said Jason Coloma, chief executive officer of Maze. “We remain on track to report key mechanistic biomarker data from our Phase 1 study of MZE782 in Q3, a significant milestone toward initiating Phase 2 trials in PKU and CKD. In addition, we continue to enroll our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, keeping us on track for an initial proof-of-concept readout in Q1 2026. With a strong balance sheet and cash runway into the second half of 2027, we’re well-positioned to deliver meaningful impact for patients and value for shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock
- Maze Therapeutics initiated with a Buy at H.C. Wainwright
- Maze Therapeutics participates in a conference call with JPMorgan
- Wedbush bullish on Maze Therapeutics, initiates with an Outperform
- Maze Therapeutics initiated with an Outperform at Wedbush